Investors Encouraged to Act on Allarity Therapeutics Lawsuit
Attention investors: a class-action lawsuit has officially been initiated against Allarity Therapeutics, Inc. This announcement highlights an important deadline for those who held or acquired securities of Allarity Therapeutics, Inc. The firm Glancy Prongay & Murray LLP is urging individuals to file a lead plaintiff motion by a critical date.
Understanding the Class Action Deadline
Glancy Prongay & Murray LLP (GPM) is reminding potential class action members that to safeguard their rights, they must file their motions by November 12, 2024. This opportunity is vital for investors who might have experienced losses related to their investments during a specific period outlined within the lawsuit.
Who is Affected?
If you purchased or acquired Allarity securities between May 17, 2022, and July 19, 2024, you could be part of this class-action suit. Those affected are encouraged to consider their options carefully, as participation could facilitate recovery for losses incurred during this timeframe.
Significant Declines in Stock Value
Several pivotal moments have caused considerable fluctuations in Allarity's stock value. The company's announcement on February 6, 2023, indicating it was under investigation by the SEC for possible violations, led to a sharp decline in their stock price, falling 3.8% to close at $0.228 per share.
Impact of Executive Changes
Adding to the turbulence, Allarity announced the termination of its CEO on December 11, 2023. This news further impacted investor confidence, resulting in a 13.4% drop in stock price, bringing it down to $0.486 per share on that day. Each of these disclosures has raised concerns among investors regarding the company’s future.
Legal Allegations Against Allarity
The lawsuit claims that throughout the specified Class Period, Allarity Therapeutics made misleading statements about its operations and regulatory submissions. Allegations suggest that the firm did not disclose critical information related to the performance and prospects of its drug Dovitinib.
The Nature of Misleading Statements
Investors are particularly concerned about the implications of the alleged deceptive practices. The complaint outlines claims that Allarity overstated the drug's regulatory prospects and failed to reveal significant legal and regulatory risks. These actions have left investors in a precarious position, and their faith in the company is severely shaken.
Next Steps for Investors
To participate in the ongoing class action, you aren’t required to take immediate action – you may choose to consult legal counsel or remain an absent member of the class. If you are considering pursuing this further, now is the time to educate yourself about your rights. You can still engage with GPM to learn more about your options.
Contact Information for Inquiries
For those interested in finding out more about the class-action lawsuit and possibly filing a motion, you can reach out directly to Charles H. Linehan at Glancy Prongay & Murray LLP. His offices are located in Los Angeles, and you can contact him through telephone at 310-201-9150 or toll-free at 888-773-9224. Email inquiries can be sent to shareholders@glancylaw.com.
Frequently Asked Questions
1. What is the class action lawsuit against Allarity Therapeutics?
The lawsuit is a legal proceeding initiated on behalf of investors who purchased Allarity securities within a specific timeframe and claimed they suffered losses.
2. What is the deadline to join this class action?
Investors must file their lead plaintiff motions by November 12, 2024, to be eligible to participate.
3. What caused the decline in Allarity's stock price?
Stock price declines were triggered by SEC investigations, changes in leadership, and failure to disclose material facts that impacted investor confidence.
4. How can I find out if I am eligible to be part of the lawsuit?
If you acquired Allarity securities between May 17, 2022, and July 19, 2024, you may be eligible. It is recommended to seek legal advice.
5. Who can I contact for more information?
Investors can contact Charles H. Linehan of Glancy Prongay & Murray LLP for detailed inquiries about participation and further actions regarding the lawsuit.
